Amdizalisib is under clinical development by Hutchison MediPharma and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase I drugs for Nodal Marginal Zone B-Cell Lymphoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amdizalisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amdizalisib (HMPL-689) is under development for the treatment of hematological B cell malignancies including chronic lymphocytic leukemia (CLL), indolent non-hodgkin lymphoma, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), Waldenstrom macroglobulinemia (WM), peripheral T-cell lymphomas (PTCL) and mantle cell lymphoma (MCL). It is administered orally. The drug candidate is a small molecule that targets PI3K Delta. HMPL-689 was also under development for the treatment of hematological malignancies diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma. The drug candidate is a new molecular entity (NME).
It was under development for the treatment of indolent non-hodgkin lymphoma.
Hutchison MediPharma overview
Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.
For a complete picture of Amdizalisib’s drug-specific PTSR and LoA scores, buy the report here.